Ind-Swift Lab. Peer Comparison

Snapshot Summary

Ind-Swift Laboratories Ltd. demonstrates a unique financial profile with exceptional profitability metrics; however, it suffers from significant revenue decline. Comparatively, while it holds the highest ROE and low valuation ratios, the sector shows a mix of strong growth and risky financial profiles among peers. Companies like Cipla and Dr. Reddy's demonstrate solid growth and profitability, making them strong contenders in the sector.

• Ind-Swift has the highest ROE (58.97%) and lowest PE (1.96) among peers.
• Cipla and Dr. Reddy's lead in profitability with solid margins and decent growth rates.
• Sun Pharma and Divi's Labs are overvalued based on PE and PEG ratios, while Ind-Swift appears undervalued.
• Financially, companies like Torrent Pharmaceuticals and Mankind Pharma present growth potential but with moderate debt ratios.

• Ind-Swift Laboratories Ltd.: Highest ROE (58.97%) and lowest PE (1.96) indicate strong profitability and valuation attractiveness.
• Cipla Ltd.: Consistent revenue growth and solid profitability metrics make it a sector leader.
• Dr. Reddy's Laboratories Ltd.: Strong EPS growth and reasonable valuation metrics support its competitive position.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
INDSWFTLAB	₹102.22	₹837.99Cr	3.62	24.68%	24.24%	0.03
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Ind-Swift Lab. Peer Comparison

Snapshot Summary